This page contains a Flash digital edition of a book.
Available treatments: PAH


5. Letairis®


eu/ema/ (accessed 23 October 2015). Prescribing Information, 2014.


6. Galiè N et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117(23):3010–19.


7. Badesch DB et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther 2012;30(2):93–9.


8. Rubin LJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346(12):896–903.


9. Galiè N et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008;371(9630):2093–100.


10. Pulido T et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809–18.


11. Galiè N et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148–57.


12. Rubin LJ et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest 2011;140(5):1274–83.


13. Galiè N et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119(22):2894–903.


14. Oudiz RJ et al. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. J Am Coll Cardiol 2012;60(8):768–74.


15. Ghofrani HA et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013;369(4):330–40.


16. Flolan® 22 Prescribing Information, 2011.


17. Barst RJ et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with


www.hospitalpharmacyeurope.com


conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296–302.


18. Simmoneau G et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165(6):800–4.


19. Jing ZC et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation 2013;127(5):624–33.


20. McLaughlin VV et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010;55(18):1915–22.


21. Olschewski H et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347(5):322–9.


22. Galiè N et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39(9):1496–502.


23. Barst RJ et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41: 219–25.


24. Galiè N et al. Effect of selexipag on morbidity/ mortality in pulmonary arterial hypertension: Results of the GRIPHON Study. J Heart Lung Transpl 2015;34(4):S163.


25. McLaughlin VV et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J 2015;46(2):405–13.


26. Galiè N et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med 2015;373(9):834–44.


27. Hoeper MM et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006;28(4): 691–4.


28. Humbert M et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24(3):353–9.


29. Simonneau G et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008;149(8): 521–30.


30. Simonneau G et al. Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2014;33(7):689–97.


31. Tapson VF et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012;142(6):1383–90.


32. Tapson VF et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest 2013;144(3):952–8.


33. Galiè N et al. A placebo-controlled, double-blind phase II interaction study to evaluate blood pressure following addition of riociguat to patients with symptomatic pulmonary arterial hypertension (PAH) receiving sildenafil (PATENT PLUS). Am J Resp Crit Care Med 2013;187:A3530.


34. McLaughlin VV et al. Treatment goals of pulmonary hypertension. J Am Coll Cardiol 2013;62(25 Suppl):D73–D81.


35. Hoeper MM et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005;26(5):858–63.


36. Rubin LJ et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Int Med 1990;112:485–91.


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48